Table 1.
Anthropometric, clinical and lifestyle data for High (N = 39) and Low (N = 37) Candida groups
| Variable | N | High N = 381 | Low N = 371 | p-value2 | Variable | N | High N = 381 | Low N = 371 | p-value2 |
|---|---|---|---|---|---|---|---|---|---|
| Sex | 75 | 0.7 | Alcohol | 75 | 0.5 | ||||
| Female | 17 (45%) | 14 (38%) | Never | 19 (50%) | 16 (43%) | ||||
| Male | 21 (55%) | 23 (62%) | Current | 3 (7.9%) | 6 (16%) | ||||
| Age | 75 | 69 (64, 74) | 65 (63, 69) | 0.2 | Former | 2 (5.3%) | 4 (11%) | ||
| Body Mass Index | 75 | 24.1 (21.4, 28.3) | 28.7 (25.9, 32.8) | 0.006 | Occasionally | 14 (37%) | 11 (30%) | ||
| Antibiotic Use Before therapy | 74 | 0.3 | Histology | 75 | 0.7 | ||||
| No | 34 (92%) | 30 (81%) | Adenocarcino | 22 (58%) | 18 (49%) | ||||
| Yes | 3 (8.1%) | 7 (19%) | Squamous | 13 (34%) | 15 (41%) | ||||
| Unknown | 1 | 0 | Other | 3 (7.9%) | 4 (11%) | ||||
| Antibiotic Use After therapy | 72 | 0.14 | Immunotherapy Drug | 75 | 0.7 | ||||
| No | 28 (76%) | 32 (91%) | nivolumab | 21 (55%) | 23 (62%) | ||||
| Yes | 9 (24%) | 3 (8.6%) | pembrolizuma | 17 (45%) | 14 (38%) | ||||
| Unknown | 1 | 2 | Responder | 75 | >0.9 | ||||
| Line of Treatment | 75 | 0.78 | Yes | 13 (34%) | 14 (38%) | ||||
| First Line | 9 (24%) | 7 (19%) | No | 25 (66%) | 23 (62%) | ||||
| Subsequent Line | 29 (76%) | 30 (81%) | COPD | 75 | 0.7 | ||||
| Without | 16 (42%) | 18 (49%) | |||||||
| With | 22 (58%) | 19 (51%) |
1Statistics presented: n (%); Median (IQR).
2Statistical tests performed: chi-square test of independence; Wilcoxon rank-sum test; Fisher’s exact test.